Stoke Therapeutics reinstated with Neutral from Overweight at JPMorgan

JPMorgan downgraded Stoke Therapeutics to Neutral from Overweight with a $6 price target after reinstating coverage of the name. While the firm likes Stoke’s proprietary platform TANGO. it thinks the mid-year STK-001 data left unanswered questions and believes the near-term uncertainty around STK-001’s efficacy and registrational trial design could limit share outperformance.